SCHEMBL2385779

SCHEMBL2385779

C=C[C@H](COS(=O)(=O)c1ccc(C)cc1)[C@@H]1CO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
DHODH Q02127 1/20 0.36
STAT3 P40763 1/20 0.35
CYP2D6 P10635 4/20 0.35
CYP1A2 P05177 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
TLR9 Q9NR96 1/20 0.34
C5AR1 P21730 1/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
VDR P11473 1/20 0.33
ALDH1A1 P00352 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
G6PD P11413 1/20 0.33
TSHR P16473 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385783 1.00 MEN1 (0.38) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2385785 1.00 MEN1 (0.38) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2385391 0.83 DHODH (0.36) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2385397 0.83 DHODH (0.36) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2385387 0.83 DHODH (0.36) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2387012 0.81 MEN1 (0.40) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL2387009 0.81 MEN1 (0.40) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL30500515 0.81 MEN1 (0.40) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL28722155 0.79 MEN1 (0.39) MEN1KMT2ADHODHSTAT3CYP2D6
SCHEMBL15291920 0.78 DHODH (0.39) MEN1KMT2ADHODHSTAT3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 MEN1 3118/4885KMT2A 568/4885DHODH 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.